Geron (GERN) falls 12.7% AH after stating it's discontinuing further development of its stem...

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN) falls 12.7% AH after stating it's discontinuing further development of its stem cell drug products, and will focus its resources on its cancer drug programs. As a result, Geron expects to cut 38% of its workforce. The company adds it's looking to find partners to "enable further development" of its stem-cell programs.